CSF1R and osteosarcoma: The FDA-approved CSF1R inhibitor Pexidartinib was previously shown to efficiently deplete Tumor-associated macrophages (TAMs) in osteosarcomas.44 In fracture healing, Csf1r expression was limited to macrophages and osteoclasts and increased in MTI (Fig. S8c–f).